

## Renal Resistive Index Is Associated With Inactive Matrix Gla ( $\gamma$ -Carboxyglutamate) Protein in an Adult Population-Based Study

David A. Jaques, MD;\* Edward Pivin, MD;\* Menno Pruijm, MD; Daniel Ackermann, MD; Idris Guessous, MD, PhD; Georg Ehret, MD; Fang-Fei Wei, MD; Jan A. Staessen, MD, PhD; Antoinette Pechère-Bertschi, MD; Cees Vermeer, PhD; Bruno Vogt, MD; Michel Burnier, MD; Pierre-Yves Martin, MD; Murielle Bochud, MD, PhD; Belen Ponte, MD

**Background**—Increased renal resistive index (RRI) has been associated with target organ damage as well as renal and cardiovascular outcomes. Matrix Gla ( $\gamma$ -carboxyglutamate) protein (MGP) is a strong inhibitor of soft tissue calcification. Its inactive form (dephospho-uncarboxylated MGP [dp-ucMGP]) has been associated with vascular stiffness, cardiovascular outcomes, and mortality. In this study, we hypothesized that high levels of dp-ucMGP were associated with increased RRI.

**Methods and Results**—We recruited participants via a multicenter family-based cross-sectional study in Switzerland. Levels of dp-ucMGP were measured in plasma by sandwich ELISA. RRI was measured by Doppler ultrasound in 3 segmental arteries in both kidneys. We used mixed regression models to assess the relationship between dp-ucMGP and RRI. We adjusted for common determinants of RRI as well as renal function and cardiovascular risk factors. We included 1006 participants in our analyses: 526 women and 480 men. Mean values were  $0.44 \pm 0.20$  nmol/L for dp-ucMGP and  $64 \pm 5\%$  for RRI. After multivariable adjustment, dp-ucMGP was positively associated with RRI ( $P=0.001$ ). In subgroup analysis by age tertiles, this association was not significant in the youngest age group ( $<38$  years;  $P=0.62$ ), whereas it was significant in older age groups (38–55 and  $>55$  years;  $P=0.016$  and  $P<0.001$ , respectively).

**Conclusions**—Levels of dp-ucMGP are positively and independently associated with RRI after adjustment for common determinants of RRI, cardiovascular risk factors, and renal function. The stronger association among older adults is probably due, in part, to age-related arterial stiffness. RRI thus seems to reflect the global atherosclerotic burden in a general adult population. (*J Am Heart Assoc.* 2019;8:e013558. DOI: 10.1161/JAHA.119.013558.)

**Key Words:** atherosclerosis • matrix Gla ( $\gamma$ -carboxyglutamate) protein • pulse pressure • pulse wave velocity • renal physiology • renal resistive index • vascular stiffness

Renal resistive index (RRI) is the difference between the maximum systolic velocity and the end-diastolic velocity divided by the maximum systolic velocity. Velocities are measured by renal Doppler ultrasound of interlobar arteries.<sup>1</sup> Despite use for several decades, the clinical interpretation of RRI remains unclear. In a population-based study that included people with mainly preserved renal function and normal renal ultrasound, factors associated with RRI were sex,

age, blood pressure (BP), heart rate (HR), and body mass index (BMI).<sup>2</sup> In patients with kidney disease, RRI correlated with the renal pathological process itself.<sup>3</sup> In contrast, in kidney transplant recipients, RRI depended mainly on systemic vascular properties.<sup>4</sup> Moreover, an elevated RRI could serve as a marker of target organ damage, as RRI is associated with adverse renal and cardiovascular outcomes.<sup>5</sup> This latter finding supports the hypothesis that intrinsic renal

From the Divisions of Nephrology (D.A.J., P.-Y.M., B.P.), Cardiology (G.E.), Hypertension (A.P.-B.), and Primary Care Medicine, Department of Primary Care Medicine (I.G.), Geneva University Hospitals, Geneva, Switzerland; Division of Chronic Disease, University Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland (E.P., M. Bochud, B.P.); Division of Nephrology and Hypertension, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland (M.P., M. Burnier); University Clinic for Nephrology, Hypertension and Clinical Pharmacology, Bern University Hospital, Bern, Switzerland (D.A., B.V.); Studies Coordinating Centre, Research Unit of Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (F.-F.W., J.A.S.); R&D Group VitaK, Maastricht University, Maastricht, The Netherlands (C.V.).

Accompanying Tables S1, S2 and Figures S1, S2 are available at <https://www.ahajournals.org/doi/suppl/10.1161/JAHA.119.013558>

\*Dr Jaques and Dr Pivin contributed equally to this work.

Some preliminary data were presented as an oral presentation at the European Society of Hypertension Annual Meeting, June 12 to 15, 2015, in Milan, Italy.

**Correspondence to:** David A. Jaques, MD, Division of Nephrology, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland. E-mail: david.jaques@hcuge.ch

Received June 11, 2019; accepted August 9, 2019.

© 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

## Clinical Perspective

### What Is New?

- We assessed the relationship between renal resistive index and the inactive form of matrix Gla ( $\gamma$ -carboxyglutamate) protein (dephospho-uncarboxylated matrix Gla protein) as a marker of systemic vascular calcification in a general adult population.
- Renal resistive index was positively associated with levels of dephospho-uncarboxylated matrix Gla protein, independent of common determinants of renal resistive index, cardiovascular risk factors, and renal function.

### What Are the Clinical Implications?

- These findings suggest that renal resistive index reflects the global atherosclerotic burden in healthy participants and could identify patients who might benefit from vitamin K supplementation.
- Whether this supplementation would result in a meaningful improvement in clinical outcome remains to be demonstrated in randomized controlled trials.

resistance is only a minor determinant of RRI and that RRI depends mainly on extrarenal systemic hemodynamic parameters such as pulse pressure (PP) and vascular compliance.<sup>6</sup> High PP and/or low vascular compliance would thus be the main predictors of elevated RRI. This theoretical view is supported by some experimental evidence, but information from clinical studies in humans remains sparse.<sup>7–9</sup>

Matrix Gla ( $\gamma$ -carboxyglutamate) protein (MGP) is a strong inhibitor of soft tissue calcification.<sup>10,11</sup> MGP knockout mice develop massive vascular calcification in their first weeks of life and die within 2 months of vessel rupture.<sup>12</sup> To acquire its full calcification inhibitory activity, MGP needs to undergo 2 posttranslational modifications. Consequently, 4 different MGP conformations can be found: (1) unmodified and inactive dephospho-uncarboxylated MGP (dp-ucMGP), (2) phosphorylated only, (3) carboxylated only, and (4) fully modified and active phosphorylated and carboxylated MGP.<sup>13,14</sup> Carboxylation of MGP is a vitamin K–dependent process because vitamin K hydroquinone is an active cofactor of the carboxylation of glutamate residues into Gla.<sup>15</sup> Therefore, dp-ucMGP is an inverse marker of vitamin K status, in which high circulating levels reflect poor vitamin K stores.<sup>16</sup> Active MGP adsorbs extracellular hydroxyapatite, inhibiting crystal growth.<sup>15</sup> It also inhibits vascular smooth muscle cell apoptosis by binding to BMP2 (bone morphogenetic protein 2), a proapoptotic agonist.<sup>17</sup> Active MGP protects the microcirculation and organ function.<sup>18</sup> Levels of dp-ucMGP have been associated with vascular stiffness measured by carotid–femoral pulse wave velocity (PWV) in 2 population-based independent studies involving >1000 participants.<sup>19,20</sup>

To clarify the pathophysiological and clinical meaning of RRI in the general adult population, we assessed whether RRI was associated with dp-ucMGP as a marker of systemic vascular calcification.

## Methods

The data that support the findings of this study are available from the corresponding author upon reasonable request.

## Participant Selection

SKIPOGH (Swiss Kidney Project on Genes in Hypertension) is a family-based cross-sectional study exploring the role of genes and kidney hemodynamics in BP regulation and kidney function in the general population.<sup>21</sup> From December 2009 to March 2013, adult participants were recruited in 2 regions (Bern and Geneva) and 1 city (Lausanne) in Switzerland. The population-sampling method has been described in detail previously.<sup>21</sup> Inclusion criteria were (1) a minimum of 18 years of age, (2) European ancestry, (3) first-degree family members who were willing to participate, and (4) written informed consent. Pregnant or breastfeeding women were not included. The institutional ethics committees of the participating university hospitals approved the SKIPOGH study.

## Study Visit

Participants were seen in the morning after an overnight fast. BP was measured 5 times after a resting period of  $\geq 10$  minutes in the sitting position with a nonmercury manual auscultatory sphygmomanometer (A&D UM-101), according to the guidelines of the European Society of Hypertension.<sup>22</sup> For the analyses, we used the mean of the last 4 BP and HR measurements.

## Laboratory Data

Blood venous samples were drawn after an overnight fast. Blood glucose, electrolytes, kidney and liver function tests, serum cholesterol, and triglycerides were analyzed by standard clinical laboratory methods. Levels of dp-ucMGP were assessed in EDTA plasma using the InaKtif iSYS Kit (IDS), which is a precommercial dual-antibody test based on the sandwich ELISA, developed by VitaK (Maastricht University, The Netherlands). Intra-assay variation coefficients are 3.1% for the upper limit of the normal range and 5.4% for the lower limit of the normal range. Interassay variation coefficients are 6.9% for the upper limit of the normal range and 13.6% for the lower limit of the normal range (Unpublished data from Cees Vermeer, PhD, R&D Group VitaK, Maastricht University, Maastricht, The Netherlands).

## Renal Doppler Ultrasound

In each study center, the same experienced operator performed renal gray-scale and color duplex ultrasounds, according to a standardized procedure, as described previously.<sup>2</sup> Briefly, RRI was measured in 3 segmental arteries (superior, middle, and inferior) of each kidney. The values were then averaged to obtain a mean value for each participant. The reproducibility of RRI measurements was assessed in a subgroup of 20 unrelated participants with inter- and intraobserver Lin correlation coefficients of 0.75 and 0.89, respectively, for the right kidney and 0.69 and 0.72, respectively, for the left kidney. Values were multiplied by 100 to express the RRI results as percentages.

## Pulse Wave Velocity

Arterial waveforms were assessed during an 8-second period in the supine position after 15 minutes of rest at the carotid and femoral arteries by applanation tonometry, using a high-fidelity SPC-301 micromanometer (Millar Instruments), interfaced with a laptop computer running the SphygmoCor software v8.0 or v8.2 (AtCor Medical). In each study center, the same experienced operator obtained the arterial waveforms and recorded carotid–femoral PWV, as described previously.<sup>19</sup>

## Definitions

Diabetes mellitus was defined as present when reported or treated or when fasting blood glucose level was  $\geq 7$  mmol/L. Hypertension was considered present when treated or when mean office BP was  $\geq 140/90$  mm Hg, according to European guidelines.<sup>22</sup> PP was defined as systolic BP (SBP) minus diastolic BP (DBP). The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula was used to estimate glomerular filtration rate (eGFR), and an eGFR  $< 60$  mL/min per  $1.73 \text{ m}^2$  defined chronic kidney disease. Kidney ultrasound was considered abnormal in any case of unilateral kidney, cysts, atrophy, stone, hydronephrosis, partial nephrectomy, suspected renal artery stenosis, horseshoe kidney, or any other kidney malformation.

## Statistical Analysis

Continuous variables are expressed as mean  $\pm$  SD and categorical variables as number and relative frequencies. Normality of distribution was assessed graphically. Outliers were defined as participants with RRI or dp-ucMGP values  $> 99$ th or  $< 1$ st percentile. RRI was divided in tertiles to assess associations with baseline characteristics. Variables were compared using  $\chi^2$  tests and ANOVA or Kruskal–Wallis tests (depending on normality and homoscedasticity) for

categorical and continuous variables, respectively, and Cuzick trend tests.

In univariable linear regression analysis, we explored the relationship of RRI with the following variables: dp-ucMGP, age, height, BMI, HR, eGFR, LDL (low-density lipoprotein), HDL (high-density lipoprotein), glucose, SBP, DBP, sex, smoking status, diabetes mellitus, antihypertensive treatment, dyslipidemia treatment, and cardiovascular disease (CVD).

To characterize the relationship between RRI and dp-ucMGP, multiple linear regressions were conducted using a backward stepwise approach, and in the final model, only variables with  $P < 0.05$  were kept. In a first step, variables associated with RRI were identified, omitting dp-ucMGP. Similarly, variables associated with dp-ucMGP were identified, omitting RRI. Then we set a model including as covariates all variables yielded from the previous 2 steps, with dp-ucMGP as the factor of interest and RRI as the outcome. Because age has been demonstrated to have a quadratic relationship with RRI, age and the square of age were included in multivariable models.<sup>2</sup> All models were treated as mixed models with the participant's family as the clustering variable and intercept as a random effect. All models were also adjusted for study center as a fixed effect. Results are presented as  $\beta$  coefficients (corresponding to a 1-U increment for continuous variables or difference between 2 categories in categorical variables) and associated 95% CIs and  $P$  values. An alternative analysis used mixed multivariable logistic regression with dp-ucMGP  $> 70\%$  as the dependent variable. The other characteristics of this model were identical to our main linear model.

In the final multivariable model, we looked for a modification effect or interaction between dp-ucMGP and the following variables: abnormal kidney on ultrasound, sex, chronic kidney disease, antihypertensive treatment, hypertension, and age. Because age has a quadratic relationship with RRI, this variable was divided in tertiles to allow interaction testing. The likelihood ratio test (LRT) was used to compare models with and without interaction terms. Linearity was assessed graphically by scatterplots and by LRT comparing models including the variable as continuous versus categorical.

As secondary analyses, we explored the relationship among RRI, PP, and PWV. In a first multivariable regression, only PP and PWV were considered as independent variables. In a second multivariable regression model, factors associated with RRI in our main model (except dp-ucMGP) were introduced as independent variables.

Data were considered to be missing completely at random; therefore, patients with any missing variables were excluded from the multivariable analyses. Statistical analyses were conducted using STATA v15 (StataCorp).  $P < 0.05$  was considered significant. For interactions, the  $P$  value was set at  $< 0.1$  for interaction terms and/or LRT.

**Table 1.** Patients Characteristics According to Tertiles of RRI (n=1006, Without Outliers)

| Characteristics                                | n    | Overall    | Low RRI (<61%)<br>n=347 | Medium RRI (61–65%)<br>n=333 | High RRI (>65%)<br>n=326 | P Value           |
|--|------|------------|-------------------------|------------------------------|--------------------------|-------------------|
| RRI mean value %                               | 1006 | 64±5       | 58±2                    | 63±1                         | 70±3                     | <0.001            |
| Categorical variables and comorbidities, n (%) |      |            |                         |                              |                          |                   |
| Female   | 1006 | 526 (52.3) | 151 (43.5)              | 177 (53.2)                   | 198 (60.7)               | <0.001            |
| Smoker   | 1006 | 243 (24.2) | 94 (27.1)               | 84 (25.2)                    | 65 (19.9)                | 0.08*             |
| Diabetes mellitus                              | 996  | 34 (3.4)   | 3 (0.9)                 | 5 (1.5)                      | 26 (8.1)                 | <0.001            |
| Hypertension                                   | 1002 | 222 (22.2) | 42 (12.2)               | 50 (15)                      | 130 (40.1)               | <0.001            |
| BP-lowering drugs                              | 1003 | 151 (15.1) | 23 (6.7)                | 34 (10.2)                    | 94 (28.9)                | <0.001            |
| Lipid-lowering drugs                           | 1003 | 39 (3.9)   | 4 (1.2)                 | 17 (5.1)                     | 18 (5.5)                 | 0.01              |
| CVD  | 994  | 99 (10.0)  | 16 (4.7)                | 34 (10.2)                    | 49 (15.4)                | <0.001            |
| Abnormal kidney                                | 999  | 189 (18.9) | 40 (11.7)               | 67 (20.2)                    | 82 (25.2)                | <0.001            |
| CKD  | 1006 | 23 (2.3)   | 3 (0.9)                 | 1 (0.3)                      | 19 (5.8)                 | <0.001            |
| Clinical characteristics, mean±SD              |      |            |                         |                              |                          |                   |
| Age, y   | 1006 | 46.7±17.2  | 38.6±13.0               | 44.2±15.2                    | 58.1±17.1                | <0.001            |
| Height, cm                                     | 1006 | 171±9      | 173±9                   | 171±9                        | 167±9                    | <0.001            |
| BMI, kg/m <sup>2</sup>                         | 1006 | 25.0±4.5   | 24.0±3.8                | 25.2±5.0                     | 25.8±4.5                 | <0.001            |
| SBP, mm Hg                                     | 1005 | 117±16     | 112±12                  | 114±14                       | 125±20                   | <0.001            |
| DBP, mm Hg                                     | 1005 | 75.5±9.7   | 76.6±9.6                | 74.8±9.2                     | 75.1±10.3                | 0.04              |
| PP, mm Hg                                      | 1005 | 41.5±11.8  | 35.8±7.5                | 39.5±8.5                     | 49.7±13.7                | <0.001            |
| HR, beats/min                                  | 999  | 66.7±10.7  | 67.6±11.0               | 66.1±10.7                    | 66.2±10.2                | 0.1               |
| Laboratory characteristics, mean±SD            |      |            |                         |                              |                          |                   |
| dp-ucMGP, nmol/L                               | 1006 | 0.44±0.20  | 0.39±0.17               | 0.43±0.20                    | 0.52±0.22                | <0.001            |
| GFR, mL/min/1.73 m <sup>2</sup>                | 1000 | 97.2±17.3  | 104±15                  | 99.1±15.2                    | 88.1±18.0                | <0.001            |
| LDL, mmol/L                                    | 995  | 3.11±0.92  | 3.05±0.92               | 3.11±0.90                    | 3.19±0.94                | 0.12 <sup>†</sup> |
| HDL, mmol/L                                    | 999  | 1.51±0.42  | 1.50±0.41               | 1.51±0.42                    | 1.51±0.43                | 0.98              |
| Glucose, mmol/L                                | 1000 | 5.16±0.72  | 4.96±0.58               | 5.08±0.55                    | 5.46±0.90                | <0.001            |
| PWV, m/s                                       | 923  | 7.90±2.22  | 7.14±1.37               | 7.53±1.82                    | 9.08±2.76                | <0.001            |

BMI indicates body mass index; BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; dp-ucMGP, dephospho-uncarboxylated matrix Gla ( $\gamma$ -carboxyglutamate) protein; GFR, glomerular filtration rate; HDL, high-density lipoprotein; HR, heart rate; LDL, low-density lipoprotein; PP, pulse pressure; PWV, pulse wave velocity; RRI, renal resistive index; SBP, systolic blood pressure.

\* $P=0.03$  for trend.

<sup>†</sup> $P=0.04$  for trend.

## Results

The complete SKIPOGH cohort included 1128 participants. For these analyses, we excluded 4 participants on anti-vitamin K medication and 80 with missing data on RRI and/or dp-ucMGP. Among the 1044 remaining participants, 38 were outliers, leaving 1006 for the main analyses (Figure S1).

Mean values of RRI and dp-ucMGP were 64±5% and 0.44±0.20 nmol/L, respectively. In total, 128 of 1006 patients (12.7%) had RRI values >70%. Overall, 52.3% were women, and mean age was 46.7±17.2 years. Participant characteristics are described according to RRI tertiles in Table 1. Low, medium, and high RRI tertile values were

<61%, 61% to 65% and >65%, respectively. Women had higher RRIs than men ( $P<0.001$ ). Across increasing tertiles of RRI, more participants had diabetes mellitus, hypertension, chronic kidney disease, history of cardiovascular disease, BP- and lipid-lowering drugs, or abnormality on kidney ultrasound (all  $P<0.05$ ). There was a trend only toward fewer smokers in higher RRI tertiles. Dp-ucMGP, PWV, age, BMI, glucose, and SBP increased within RRI tertiles (all  $P<0.001$ ), whereas height, eGFR, and DBP decreased with higher categories of RRI (all  $P<0.05$ ). There was a trend only toward higher LDL and fewer smokers across increasing tertiles (for trend,  $P=0.04$  and  $P=0.03$ , respectively).

**Table 2.** Factors Associated With RRI in Univariable and Multivariable Mixed Linear Regression Models (n=970 for All Models, Without Outliers)

| Independent Variable            | Univariable Model |                |         | Full Model |                |         | Final Model |                |         |
|---------------------------------|-------------------|----------------|---------|------------|----------------|---------|-------------|----------------|---------|
|                                 | $\beta$           | 95% CI         | P Value | $\beta$    | 95% CI         | P Value | $\beta$     | 95% CI         | P Value |
| dp-ucMGP, nmol/L                | 8.06              | 6.60–9.53      | <0.001  | 2.17       | 0.96–3.42      | 0.001   | 2.18        | 0.96–3.41      | 0.001   |
| Sex (female)                    | 1.63              | 1.03–2.22      | <0.001  | 1.88       | 1.19–2.57      | <0.001  | 1.73        | 1.27–2.18      | <0.001  |
| Smoker (yes)                    | –1.08             | –1.80 to –0.37 | 0.003   | 0.29       | –0.21 to 0.79  | 0.26    | ...         | ...            | ...     |
| Diabetes mellitus (yes)         | 6.24              | 4.62–7.87      | <0.001  | 0.64       | –0.71 to 1.98  | 0.35    | ...         | ...            | ...     |
| BP drugs (yes)                  | 4.60              | 3.79–5.41      | <0.001  | 0.19       | –0.49 to 0.87  | 0.59    | ...         | ...            | ...     |
| Lipid drugs (yes)               | 2.54              | 0.93–4.16      | 0.002   | –0.55      | –1.68 to 0.59  | 0.35    | ...         | ...            | ...     |
| CVD (yes)                       | 3.95              | 2.96–4.93      | <0.001  | 0.51       | –0.23 to 1.24  | 0.18    | ...         | ...            | ...     |
| Age, y                          | –0.33             | –0.40 to –0.26 | <0.001  | –0.15      | –0.23 to –0.07 | <0.001  | –0.16       | –0.23 to –0.08 | <0.001  |
| Age <sup>2</sup> , y            | 0.01              | 0.004–0.006    | <0.001  | 0.003      | 0.002–0.003    | <0.001  | 0.003       | 0.002–0.004    | <0.001  |
| Body height, cm                 | –0.17             | –0.20 to –0.14 | <0.001  | –0.01      | –0.04 to 0.03  | 0.79    | ...         | ...            | ...     |
| BMI, kg/m <sup>2</sup>          | 0.19              | 0.12–0.26      | <0.001  | 0.06       | 0.00–0.12      | 0.049   | 0.08        | 0.02–0.14      | 0.006   |
| SBP, mm Hg                      | 0.11              | 0.09–0.13      | <0.001  | 0.12       | 0.10–0.15      | <0.001  | 0.13        | 0.10–0.15      | <0.001  |
| DBP, mm Hg                      | –0.02             | –0.06 to 0.01  | 0.15    | –0.22      | –0.25 to –0.18 | <0.001  | –0.22       | –0.26 to –0.18 | <0.001  |
| HR, beats/min                   | –0.06             | –0.09 to –0.03 | <0.001  | –0.05      | –0.07 to –0.03 | <0.001  | –0.05       | –0.07 to –0.03 | <0.001  |
| GFR, mL/min/1.73 m <sup>2</sup> | –0.12             | –0.13 to –0.10 | <0.001  | –0.001     | –0.02 to 0.02  | 0.95    | ...         | ...            | ...     |
| LDL, mmol/L                     | 0.15              | –0.19 to 0.48  | 0.39    | –0.25      | –0.51 to 0.01  | 0.06    | –0.29       | –0.54 to –0.04 | 0.025   |
| HDL, mmol/L                     | 0.24              | –0.50 to 0.99  | 0.52    | –0.58      | –1.20 to 0.04  | 0.07    | ...         | ...            | ...     |
| Glucose, mmol/L                 | 1.98              | 1.55–2.42      | <0.001  | 0.58       | 0.19–0.99      | 0.07    | 0.66        | 0.30–1.02      | <0.001  |

All models are adjusted for center as fixed effect and for family as random effect.  $\beta$  corresponds to 1-U increase. BMI indicates body mass index; BP, blood pressure; CVD, cardiovascular disease; DBP, diastolic blood pressure; dp-ucMGP, dephospho-uncarboxylated matrix Gla ( $\gamma$ -carboxyglutamate) protein; GFR, glomerular filtration rate; HDL, high density lipoprotein; HR, heart rate; LDL, low density lipoprotein; RRI, renal resistive index; SBP, systolic blood pressure.

### Association of dp-ucMGP With RRI

In univariable analyses, all independent variables except LDL, HDL, and DBP were associated with RRI (Table 2). A positive association of dp-ucMGP with RRI was noted (Figure 1): every 1-U increase in dp-ucMGP (nmol/L) increased RRI by 8.1%.


Multivariable analyses included 970 patients without missing data (Table 2). Factors associated with RRI were dp-ucMGP, sex, age, age squared, BMI, HR, LDL, glucose, SBP, and DBP (all  $P<0.05$ ). In the final model, every 1-U increase in dp-ucMGP (nmol/L) was associated with an increase of 2.2% RRI. During the backward stepwise procedure, variables were discarded in the following order: eGFR, diabetes mellitus, smoking, and history of CVD (Table S1). The following variables were discarded from the outset and thus not considered in the backward stepwise procedure, as they were not associated with either RRI or dp-ucMGP in initial multivariable models (see Methods): height, HDL, BP, and lipid-lowering drugs.

In multivariable logistic regression, dp-ucMGP was significantly associated with RRI >70% (coefficient: 2.59; 95% CI, 1.11–4.08;  $P=0.001$ ).

### Sensitivity and Secondary Analyses

In sensitivity analyses, results were globally similar when accounting for outliers (Table S2). Moreover, no interaction was found between dp-ucMGP and abnormal kidney on ultrasound, sex, chronic kidney disease, antihypertensive treatment, and hypertension (interaction term,  $P>0.1$ ; LRT,  $P>0.1$  for all). However, a significant interaction was found between dp-ucMGP and age in tertiles ( $P<0.001$  for interaction term and LRT). The strength and significance of the association between dp-ucMGP and RRI increased across tertiles of age (Figure 2). In the multivariable analysis stratified by age category, there was no significant association in the youngest group (aged 18–38 years:  $\beta=-0.53$ ; 95% CI, –2.62 to 1.56;  $P=0.62$ ), whereas the association was significant in the older groups (aged 38–55 years:  $\beta=2.58$ ; 95% CI, 0.47–4.48;  $P=0.016$ ; aged  $\geq 55$  years:  $\beta=4.62$ ; 95% CI, 2.53–6.72;  $P<0.001$ ).

In secondary analyses, PP and PWV showed a positive relationship with RRI (Pearson correlation coefficients of 0.59 and 0.45, respectively). However, graphical assessment showed nonlinearity, specifically, at the lowest PP and PWV



**Figure 1.** Scatterplot showing the association between dp-ucMGP and RRI (n=1006, without outliers). Red line represents linear regression. Pearson correlation coefficient is represented with the corresponding *P* value. dp-ucMGP indicates dephospho-uncarboxylated matrix Gla ( $\gamma$ -carboxyglutamate) protein; RRI, renal resistive index.

values (Figure S2). Because nonlinearity was confirmed by LRT, PP and PWV were used as tertiles in linear regressions. In a mixed unadjusted linear regression model, PP and PWV were both positively associated with RRI (both  $P < 0.001$ ). PP and PWV were still significantly associated with RRI after adjustment for sex, age, BMI, HR, LDL, and glucose ( $P < 0.001$  and  $P = 0.040$ , respectively).


## Discussion

In this study we observed a positive association between RRI and dp-ucMGP in a large, multicentric, family-based population. This association was independent of other variables

previously known to influence RRI (age, sex, BMI, HR, SBP, and DBP) and renal function and cardiovascular risk factors (diabetes mellitus, treated hypertension, and smoking).

## MGP as a Determinant of RRI

Soon after being introduced in 1974 as a measure of intrarenal vascular resistance, RRI was used as a potential marker of kidney damage. Indeed, RRI theoretically depends on the capillary wedge pressure, representing a combination of interstitial and venous pressures.<sup>6</sup> Any pathological process affecting one of these compartments should increase RRI. This was illustrated for the first time in 1991 in kidney biopsies, as tubulointerstitial disease was associated with higher RRI than isolated glomerulopathies.<sup>23</sup> A larger study including 992 patients with simultaneous RRI assessment and kidney biopsy also showed that tubulointerstitial injury correlated strongly with elevated RRI.<sup>3</sup> Consequently, in patients with established kidney injury, an elevated RRI reflects—at least in part—the intrarenal pathological process itself. In contrast, RRI could also reflect systemic vascular properties rather than intrarenal pathological processes. The most convincing data supporting this hypothesis thus far came from an elegant study of 321 renal transplant recipients.<sup>4</sup> In that study, RRI correlated with recipient age and central hemodynamic factors but not with histopathological findings on protocol-specified kidney biopsies. However, because that study took place in a specific population of transplanted patients, its generalizability is limited. The use of calcineurin inhibitors, known to influence the RRI, also hampered definite conclusions. The clinical interpretation of RRI is further complicated by the fact that RRI can also be seen as a marker of target kidney damage and a prognostic predictor of renal and cardiovascular outcome. Therefore, RRI



**Figure 2.** Scatterplots showing the univariable association between dp-ucMGP and RRI depending on tertiles of age (n=970, without outliers and no missing covariates). **A**, Younger tertile (first):  $\beta = -1.1$  (95% CI,  $-3.3$  to  $+1.1$ ). **B**, Middle tertile (second):  $\beta = 2.4$  (95% CI,  $0.2$ – $4.7$ ). **C**, Older tertile (third):  $\beta = 7.6$  (95% CI,  $5.1$ – $10.0$ ). Univariable *P* value for interaction  $< 0.001$ . Red line represents linear regression line. *P* values from the regression are represented. dp-ucMGP indicates dephospho-uncarboxylated matrix Gla ( $\gamma$ -carboxyglutamate) protein; RRI, renal resistive index.

was associated with albuminuria and left ventricular hypertrophy in 211 untreated hypertensive patients.<sup>24</sup> Moreover, RRI was predictive of a composite end point of cardiovascular and renal events in 426 hypertensive patients followed for a mean of 3.1 years.<sup>5</sup> Conversely, dp-ucMGP was previously associated with various cardiovascular outcomes in several populations: high dp-ucMGP levels were associated with below-knee arterial calcification scores in patients with type 2 diabetes mellitus and an increased risk of CVD independent of classical risk factors in older patients free of CVD at baseline.<sup>25,26</sup> Moreover, dp-ucMGP has already been associated with vascular calcification and arterial stiffness.<sup>19,20,27–29</sup>

Our study provides new data from the general population. The robust positive association of RRI with dp-ucMGP described in our study links RRI, for the first time, to a direct pathophysiological marker of vascular calcification. Our findings support the view that RRI is a marker of systemic atherosclerotic burden. This hypothesis is reinforced by the fact that the association between RRI and dp-ucMGP was independent of classical determinants of RRI (age, sex, BMI, HR) and, more important, from SBP and DBP. This finding further supports the idea that RRI reflects the global vascular calcification burden itself and not only systemic hemodynamic properties. Moreover, in our study, the association between RRI and dp-ucMGP was not influenced by the presence of established CVD, traditional cardiovascular risk factors (diabetes mellitus, hypertension, and smoking), renal function, and the presence of abnormality on renal ultrasound. This highlights the idea that, in a general adult population, RRI reflects global vascular calcification status despite the absence of renal and cardiovascular clinical manifestations. Globally, our findings shed new light on the intricate role of RRI as a prognostic marker of renal and cardiovascular outcomes.

Finally, age seemed to play a complex role in the relationship between dp-ucMGP and RRI. The effect and significance of dp-ucMGP on RRI increased with advancing age. However, this result is not surprising because the range of absolute dp-ucMGP values was low in younger people and thus less likely to reflect significant vascular hemodynamic impairment. Moreover, arterial stiffness is also known to increase with age.

## Determinants of RRI

Mathematical derivations also support the hypothesis that RRI depends on systemic vascular and hemodynamic factors. O'Neill stated that the RRI equation can be rewritten in the following fashion<sup>6</sup>:  $RRI = 1 - \frac{P_{dia} - P_0}{P_{sys} - P_0} \times \frac{LA_{sys}}{LA_{dia}}$ , where  $P_{sys}$  indicates systolic pressure,  $P_{dia}$  indicates diastolic pressure,  $P_0$  indicates renal capillary wedge pressure,  $LA_{sys}$  indicates

systolic vessel lumen area, and  $LA_{dia}$  indicates diastolic vessel lumen area. In most physiological situations,  $P_0$  (interstitial plus venous pressure) is negligible and RRI indirectly depends on 2 central hemodynamic parameters: PP (represented here by the ratio of  $P_{dia}/P_{sys}$ ) and vascular compliance (represented here by the ratio of  $LA_{sys}/LA_{dia}$ ). RRI thus varies directly with PP and inversely with vascular compliance. This interpretation of RRI sheds light on its dependency on extrarenal hemodynamic factors such as age, HR, and Valsalva maneuver.<sup>30–32</sup> Experimental data support this theoretical view. First, RRIs of perfused rabbit kidneys showed a strong linear correlation with PP.<sup>8</sup> Second, Hashimoto and Ito<sup>7</sup> showed that RRI was dependent on aortic PP measured by applanation tonometry and aortic compliance measured by carotid–femoral PWV in 133 hypertensive patients. However, when using multivariable analysis, only aortic PP (not aortic compliance) was independently associated with RRI, suggesting that PP was the main physiological factor. Our findings globally agree with this model. Even after accounting for a nonlinear relationship, PP measured by manual auscultatory sphygmomanometer and aortic compliance measured by carotid–femoral PWV both showed a strong positive correlation with RRI. However, PWV seemed to play a weaker role than PP; its univariable correlation with RRI was smaller, and its statistical significance in multivariable analysis decreased substantially. This result again supports the fact that PP is an independent determinant of RRI, whereas aortic compliance could merely represent a secondary effect on the causal process. Globally, our findings confirm that in a healthy adult population, RRI is strongly dependent on extrarenal systemic hemodynamic factors.

## Limitations

The main limitation of our study is the observational and cross-sectional nature of the association between RRI and dp-ucMGP, which limits causal inference. Moreover, despite adjusting for clinically relevant variables, including known confounders, we cannot exclude potential residual confounding. RRI measurements were performed in 3 different study centers. However, the center effect was accounted for in linear regressions, and interobserver reproducibility was excellent. Strengths of our study include the large sample size with >1000 participants and the population-based design, which increases its generalizability. However, this study included people of European descent, and whether similar associations exist in non-European populations remains an open question. RRI could be influenced by intra-abdominal pressure, hematoma, or cirrhosis, but because mainly healthy participants were included, we do not believe those conditions would significantly influence our results. Moreover, all

measurements were performed in expiration, which reduces the influence of intra-abdominal pressure. RRI also depends on stroke volume, which was not measured in our study. However, there is no physiological argument that adjustment for this parameter would alter the strength or direction of the association between RRI and dp-ucMGP.

## Conclusions

The robust independent positive association between RRI and dp-ucMGP suggests that RRI directly reflects the global atherosclerotic burden in a general population of healthy participants. This finding strengthens the potential role of RRI as a subclinical and prognostic marker of cardiovascular outcomes. Further prospective studies are needed to clarify whether MGP and RRI can be used as a stratification tool in the evaluation of individual cardiovascular risk.

It has already been shown that vitamin K supplementation dose-dependently decreases dp-ucMGP circulating levels and improves elastic properties of arterial vessel walls.<sup>16,33,34</sup> Our findings suggest that an elevated RRI could identify patients benefiting from such supplementation. Whether this supplementation would result in a meaningful improvement in clinical outcome remains to be demonstrated in randomized controlled trials.

## Acknowledgments

We are extremely grateful to the SKIPOGH (Swiss Kidney Project on Genes in Hypertension) study participants. We thank the nurses involved in the study and recruitment: Marie-Odile Levy, Guler Gök-Sogüt, Ulla Spüchbach, Dominique Siminski. We thank Sandrine Estoppey and Dushan Petrovic for their help with logistic and database management.

## Sources of Funding

The SKIPOGH (Swiss Kidney Project on Genes in Hypertension) study is supported by the Swiss National Science Foundation (FN 33CM30-124087 and FN 33CM30-140331). Belen Ponte was partially supported by the Swiss National Science Foundation (FN PMPDP3\_171352).

## Disclosures

None.

## References

- Chirinos JA, Townsend RR. Systemic arterial hemodynamics and the "renal resistive index": what is in a name? *J Clin Hypertens (Greenwich)*. 2014;16:170–171.
- Ponte B, Pruijm M, Ackermann D, Vuistiner P, Eisenberger U, Guessous I, Rousson V, Mohaupt MG, Alwan H, Ehret G, Pechere-Bertschi A, Paccaud F,

- Staesens JA, Vogt B, Burnier M, Martin P-Y, Bochud M. Reference values and factors associated with renal resistive index in a family-based population study. *Hypertension*. 2014;63:136–142.
- Chen Q, He F, Feng X, Luo Z, Zhang J, Zhang L, Wang Y, Tong J. Correlation of Doppler parameters with renal pathology: a study of 992 patients. *Exp Ther Med*. 2014;7:439–442.
- Naesens M, Heylen L, Lerut E, Claes K, De Wever L, Claus F, Oyen R, Kuypers D, Evenepoel P, Bammens B, Sprangers B, Meijers B, Pirenne J, Monbaliu D, de Jonge H, Metalidis C, De Vusser K, Vanreenterghem Y. Intrarenal resistive index after renal transplantation. *N Engl J Med*. 2013;369:1797–1806.
- Doi Y, Iwashima Y, Yoshihara F, Kamide K, Hayashi S, Kubota Y, Nakamura S, Horio T, Kawano Y. Renal resistive index and cardiovascular and renal outcomes in essential hypertension. *Hypertension*. 2012;60:770–777.
- O'Neill WC. Renal resistive index. *Hypertension*. 2014;64:915–917.
- Hashimoto J, Ito S. Central pulse pressure and aortic stiffness determine renal hemodynamics: pathophysiological implication for microalbuminuria in hypertension. *Hypertension*. 2011;58:839–846.
- Tublin ME, Tessler FN, Murphy ME. Correlation between renal vascular resistance, pulse pressure, and the resistive index in isolated perfused rabbit kidneys. *Radiology*. 1999;213:258–264.
- Pozniak MA, Kelcz F, Stratta RJ, Oberley TD. Extraneous factors affecting resistive index. *Invest Radiol*. 1988;23:899–904.
- Shanahan CM, Proudfoot D, Farzaneh-Far A, Weissberg PL. The role of Gla proteins in vascular calcification. *Crit Rev Eukaryot Gene Expr*. 1998;8:357–375.
- Price PA, Urist MR, Otawara Y. Matrix Gla protein, a new gamma-carboxylglutamic acid-containing protein which is associated with the organic matrix of bone. *Biochem Biophys Res Commun*. 1983;117:765–771.
- Luo G, Ducey P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. *Nature*. 1997;386:78–81.
- Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. *Arterioscler Thromb Vasc Biol*. 1998;18:1400–1407.
- Price PA, Rice JS, Williamson MK. Conserved phosphorylation of serines in the Ser-X-Glu/Ser(P) sequences of the vitamin K-dependent matrix Gla protein from shark, lamb, rat, cow, and human. *Protein Sci*. 1994;3:822–830.
- Wallin R, Cain D, Sane DC. Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells—a cell system which resembles the system in bone cells. *Thromb Haemost*. 1999;82:1764–1767.
- Dalmeijer GW, van der Schouw YT, Magdeleyns E, Ahmed N, Vermeer C, Beulens JWJ. The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein. *Atherosclerosis*. 2012;225:397–402.
- Boström K. Insights into the mechanism of vascular calcification. *Am J Cardiol*. 2001;88:20E–22E.
- Wei F-F, Trenson S, Verhamme P, Vermeer C, Staessen JA. Vitamin K-dependent matrix Gla protein as multifaceted protector of vascular and tissue integrity. *Hypertension*. 2019;73:1160–1169.
- Pivin E, Ponte B, Pruijm M, Ackermann D, Guessous I, Ehret G, Liu Y-P, Drummen NEA, Knapen MHJ, Pechere-Bertschi A, Paccaud F, Mohaupt M, Vermeer C, Staessen JA, Vogt B, Martin P-Y, Burnier M, Bochud M. Inactive matrix Gla-protein is associated with arterial stiffness in an adult population-based study. *Hypertension*. 2015;66:85–92.
- Mayer O, Seidlerová J, Wohlfahrt P, Filipovský J, Vaněk J, Cífková R, Windrichová J, Topolčan O, Knapen MHJ, Drummen NEA, Vermeer C. Desphospho-uncarboxylated matrix Gla protein is associated with increased aortic stiffness in a general population. *J Hum Hypertens*. 2016;30:418–423.
- Prujm M, Ponte B, Ackermann D, Vuistiner P, Paccaud F, Guessous I, Ehret G, Eisenberger U, Mohaupt M, Burnier M, Martin P-Y, Bochud M. Heritability, determinants and reference values of renal length: a family-based population study. *Eur Radiol*. 2013;23:2899–2905.
- Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, De Backer G, Heagerty AM, Agewall S, Bochud M, Borghi C, Boutouyrie P, Brguljan J, Bueno H, Caiani EG, Carlberg B, Chapman N, Cífková R, Cleland JGF, Collet J-P, Coman IM, de Leeuw PW, Delgado V, Dendale P, Diener H-C, Dorobantu M, Fagard R, Farsang C, Ferrini M, Graham IM, Grassi G, Haller H, Hobbs FDR, Jelakovic B, Jennings C, Katus HA, Kroon AA, Leclercq C, Lovic D, Lurbe E, Manolis AJ, McDonagh TA, Messerli F, Muijsan ML, Nixdorff U, Olsen MH, Parati G, Perk J, Piepoli MF, Polonia J, Ponikowski P, Richter DJ, Rimoldi SF, Roffi M, Sattar N, Seferovic PM, Simpson IA, Sousa-Uva M, Stanton AV, van de Borne P, Vardas P, Volpe M, Wassmann S, Windecker S,



- Zamorano JL, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet J-P, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, McDonagh TA, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Sousa-Uva M, Zamorano JL, Tsioufis C, Lurbe E, Kreutz R, Bochud M, Rosei EA, Jelakovic B, Azizi M, Januszewicz A, Kahan T, Polonia J, van de Borne P, Williams B, Borghi C, Mancia G, Parati G, Clement DL, Coca A, Manolis A, Lovic D, Benkhedda S, Zelveian P, Siostrzonek P, Najafov R, Pavlova O, De Pauw M, Dizdarevic-Hudic L, Raev D, Karpettas N, Linhart A, Olsen MH, Shaker AF, Viigimaa M, Metsärinne K, Vavlukis M, Halimi J-M, Pagava Z, Schunkert H, Thomopoulos C, Páll D, Andersen K, Shechter M, Mercurio G, Bajraktari G, Romanova T, Trušinskis K, Saade GA, Sakalyte G, Noppe S, DeMarco DC, Caraus A, Wittekoek J, Aksnes TA, Jankowski P, Polonia J, Vinereanu D, Baranova EI, Foscoli M, Dikic AD, Filipova S, Fras Z, Bertomeu-Martínez V, Carlberg B, Burkard T, Sdiri W, Aydogdu S, Sirenko Y, Brady A, Weber T, Lazareva I, De Backer T, Sokolovic S, Jelakovic B, Widimsky J, Viigimaa M, Pörsti I, Denolle T, Krämer BK, Stergiou GS, Parati G, Trušinskis K, Miglinas M, Gerds E, Tykarski A, de Carvalho Rodrigues M, Dorobantu M, Chazova I, Lovic D, Filipova S, Brguljan J, Segura J, Gottsäter A, Pechère-Bertschi A, Erdine S, Sirenko Y, Brady A. 2018 ESC/ESH guidelines for the management of arterial hypertension. *Eur Heart J*. 2018;39:3021–3104.
23. Platt JF, Ellis JH, Rubin JM, DiPietro MA, Sedman AB. Intrarenal arterial Doppler sonography in patients with nonobstructive renal disease: correlation of resistive index with biopsy findings. *AJR Am J Roentgenol*. 1990;154:1223–1227.
24. Pontremoli R, Viazzi F, Martinoli C, Ravera M, Nicoletta C, Berruti V, Leoncini G, Ruello N, Zagami P, Bezante GP, Derchi LE, Deferrari G. Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. *Nephrol Dial Transplant*. 1999;14:360–365.
25. van den Heuvel EGHM, van Schoor NM, Lips P, Magdeleyns EJP, Deeg DJH, Vermeer C, den Heijer M. Circulating uncarboxylated matrix Gla protein, a marker of vitamin K status, as a risk factor of cardiovascular disease. *Maturitas*. 2014;77:137–141.
26. Liabeuf S, Olivier B, Vemeer C, Theuwissen E, Magdeleyns E, Aubert C, Brazier M, Mentaverri R, Hartemann A, Massy ZA, Massy ZA. Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein. *Cardiovasc Diabetol*. 2014;13:85.
27. Dalmeijer GW, van der Schouw YT, Vermeer C, Magdeleyns EJ, Schurgers LJ, Beulens JWJ. Circulating matrix Gla protein is associated with coronary artery calcification and vitamin K status in healthy women. *J Nutr Biochem*. 2013;24:624–628.
28. Delanaye P, Krzesinski J-M, Warling X, Moonen M, Smelten N, Médart L, Pottel H, Cavalier E. Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients. *BMC Nephrol*. 2014;15:145.
29. Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, Magdeleyns EJ, Vermeer C, Choukroun G, Massy ZA. The circulating inactive form of matrix Gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. *Clin J Am Soc Nephrol*. 2010;5:568–575.
30. Takano R, Ando Y, Taniguchi N, Itoh K, Asano Y. Power Doppler sonography of the kidney: effect of Valsalva's maneuver. *J Clin Ultrasound*. 2001;29:384–388.
31. Mostbeck GH, Gössinger HD, Mallek R, Siostrzonek P, Schneider B, Tscholakoff D. Effect of heart rate on Doppler measurements of resistive index in renal arteries. *Radiology*. 1990;175:511–513.
32. Boddì M, Sacchi S, Lammell RM, Mohseni R, Gastone G, Serneri N. Age-related and vasomotor stimuli-induced changes in renal vascular resistance detected by Doppler ultrasound. *Am J Hypertens*. 1996;9:461–466.
33. Knapen MHJ, Braam LAJLM, Drummen NE, Bekers O, Hoeks APG, Vermeer C. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. *Thromb Haemost*. 2015;113:1135–1144.
34. Braam L, Hoeks A, Brouns F, Hamulyák K, Gerichhausen M, Vermeer C. Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: a follow-up study. *Thromb Haemost*. 2004;91:373–380.

# SUPPLEMENTAL MATERIAL

**Table S1. Backward stepwise mixed linear regression (without outliers) for RRI on 970 patients.**

| Independent variables                  | Full model |             | Step 1  |             | Step 2  |             | Step 3  |             | Step 4  |        |
|--|------------|-------------|---------|-------------|---------|-------------|---------|-------------|---------|--------|
|  | $\beta$    | p           | $\beta$ | p           | $\beta$ | p           | $\beta$ | p           | $\beta$ | p      |
| Dp-ucMGP (nmol/l)                      | 2.22       | 0.001       | 2.23    | <0.001      | 2.18    | 0.001       | 2.11    | 0.001       | 2.18    | 0.001  |
| Sex (female)                           | 1.75       | <0.001      | 1.76    | <0.001      | 1.77    | <0.001      | 1.73    | <0.001      | 1.73    | <0.001 |
| Smoker (yes)                           | 0.35       | 0.17        | 0.35    | 0.17        | 0.34    | <b>0.18</b> |         |             |         |        |
| Diabetes (yes)                         | 0.67       | 0.32        | 0.67    | <b>0.32</b> |         |             |         |             |         |        |
| CV disease (yes)                       | 0.55       | 0.14        | 0.55    | 0.14        | 0.57    | 0.12        | 0.56    | <b>0.13</b> |         |        |
| Age (years)                            | -0.16      | <0.001      | -0.16   | <0.001      | -0.16   | <0.001      | -0.16   | <0.001      | -0.16   | <0.001 |
| Age <sup>2</sup> (years <sup>2</sup> ) | 0.003      | <0.001      | 0.003   | <0.001      | 0.003   | <0.001      | 0.003   | <0.001      | 0.003   | <0.001 |
| BMI (kg/m <sup>2</sup> )               | 0.08       | 0.009       | 0.08    | 0.009       | 0.08    | 0.007       | 0.08    | 0.009       | 0.08    | 0.006  |
| SBP (mmHg)                             | 0.13       | <0.001      | 0.13    | <0.001      | 0.13    | <0.001      | 0.13    | <0.001      | 0.13    | <0.001 |
| DBP (mmHg)                             | -0.22      | <0.001      | -0.22   | <0.001      | -0.22   | <0.001      | -0.22   | <0.001      | -0.22   | <0.001 |
| Heart rate (1/min)                     | -0.05      | <0.001      | -0.05   | <0.001      | -0.05   | <0.001      | -0.05   | <0.001      | -0.05   | <0.001 |
| GFR (ml/min/m <sup>2</sup> )           | -0.001     | <b>0.90</b> |         |             |         |             |         |             |         |        |
| LDL (mmol/l)                           | -0.23      | 0.07        | -0.23   | 0.07        | -0.26   | 0.047       | -0.26   | 0.041       | -0.29   | 0.025  |

|                  |      |       |      |       |      |        |      |        |      |        |
|------------------|------|-------|------|-------|------|--------|------|--------|------|--------|
| Glucose (mmol/l) | 0.58 | 0.005 | 0.58 | 0.005 | 0.66 | <0.001 | 0.66 | <0.001 | 0.66 | <0.001 |
|------------------|------|-------|------|-------|------|--------|------|--------|------|--------|

All models adjusted for center as fixed effect.

RRI, renal resistive index; BP, blood pressure; CV, cardiovascular; CKD, chronic kidney disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; dp-ucMGP, dephospho-uncarboxylated matrix Gla protein; GFR, glomerular filtration rate; LDL, low density lipoprotein; HDL, high density lipoprotein; PWV, pulse wave velocity.

Definitions: Diabetes, reported or treated or fasting blood glucose level >7 mmol/l.


All models are adjusted for center as fixed effect and family as random effect.  $\beta$  corresponds to 1 unit increase.

**Table S2. Factors associated with RRI in multivariate mixed linear regression models with outliers but no missing covariates (N=1'025).**

| Independent variables    | Final model with extreme outliers |              |        |
|--------------------------|-----------------------------------|--------------|--------|
|                          | $\beta$                           | 95% CI       | p      |
| Dp-ucMGP (nmol/l)        | 1.71                              | 0.74; 2.67   | 0.001  |
| Sex (women)              | 1.71                              | 1.26; 2.15   | <0.001 |
| Age (years)              | -0.15                             | -0.23; -0.08 | <0.001 |
| Age <sup>2</sup> (years) | 0.003                             | 0.002; 0.004 | <0.001 |
| BMI (kg/m <sup>2</sup> ) | 0.09                              | 0.04; 0.15   | 0.001  |
| SBP (mmHg)               | 0.14                              | 0.11; 0.16   | <0.001 |
| DBP (mmHg)               | -0.24                             | -0.28; -0.20 | <0.001 |
| HR (1/min)               | -0.06                             | -0.08; -0.03 | <0.001 |
| LDL (mmol/l)             | -0.26                             | -0.50; -0.01 | 0.041  |
| Glucose (mmol/l)         | 0.71                              | 0.36; 1.07   | <0.001 |


RRI, renal resistive index; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; dp-ucMGP, dephospho-uncarboxylated matrix Gla protein; LDL, low density lipoprotein.

**Figure S1. Study flowchart.**



RRI, renal resistive index; dp-ucMGP, dephospho-uncarboxylated matrix Gla protein

**Figure S2. Scatterplots showing the univariate association between RRI, PP and PWV.**



**a. Renal Resistive Index and Pulse Pressure**

**b. Renal Resistive Index and Pulse Wave Velocity**

Pearson correlation coefficients are represented in the graph with the corresponding p-value.

RRI, renal resistive index; PP, pulse pressure; PWV, pulse wave velocity.